Hui-Kuo Shu, MD, PhD
Department of Radiation Oncology
Hui-Kuo Shu, MD, PhD, is studying how abnormal signaling in glioblastoma brain tumors leads to increased expression of a transcription factor (ID1) that is important in tumor-associated stem cells.
Through his research, Dr. Shu hopes to develop strategies that can inhibit ID1 activity or block its expression for treatment of glioblastomas.
Dr. Shu is a member of the Cancer Cell Biology research program at Winship Cancer Institute of Emory University.
Hui-Kuo Shu, MD, PhD, specializes in the treatment of brain and spine tumors. He is board certified in radiation oncology and a clinical member of the Winship Cancer Institute. He has extensive expertise in the use of advanced radiotherapy techniques including intensity-modulated radiation therapy, stereotactic radiosurgery, fractionated stereotactic radiotherapy, extracranial radiosurgery and image-guided radiation therapy.
Dr. Shu was appointed assistant professor in radiation oncology at the University of Pennsylvania in 1999. He also served as the main radiation oncologist for the treatment of pediatric brain tumors at the Children’s Hospital of Philadelphia from 2001 to 2005. He was recruited to Emory University as a physician-scientist and was appointed associate professor in the department of radiation oncology in 2005.
Outside of work, Dr. Shu enjoys spending time and traveling with his wife and three children.
Dr. Shu received his MD and PhD degrees in the NIH-sponsored Medical Scientist Training Program at Case Western Reserve University in Cleveland, Ohio. He completedpost-graduate training with a year in internal medicine at University Hospitals of Cleveland, followed by a 5-year radiation oncology residency and fellowship at the University of California in San Francisco (UCSF).
At UCSF, he received grants from the American Society for Therapeutic Radiology and Oncology and the Radiological Society of North America to fund his fellowship research on malignant nervous system tumors. He was honored with awards and appointments during his training including the American Radium Society’s Young Oncologist Essay Award, the RSNA Roentgen Resident/Fellow Research Award at UCSF and chief resident in radiation oncology.
Dr. Shu is a member of the American Society for Clinical Oncology, Pediatric Brain Tumor Consortium, American Association for Cancer Research and Society for Neuro-Oncology, among other organizations.
In the area of clinical research, Dr. Shu is a member of the neuro-oncology working group at Emory University and is actively conducting brain tumor-related clinical trials sponsored by cooperative groups such as New Agents for Brain Tumor Treatment and Radiation Therapy Oncology Group. His main research focus involves the study of glioblastomas and how to better treat these aggressive brain tumors.
He has published numerous articles in peer-reviewed journals including Proceedings of the National Academy of Sciences and Cancer Research. He also serves as a regular reviewer for several journals including Cancer Research and Cancer. His research has been funded by a number of brain tumor organizations including the Brain Tumor Foundation, American Brain Tumor Association and Childhood Brain Tumor Foundation.